Aflac 2025-26: Japan Sales +16%, US Pre-Tax 33-36% Target
FY25 revenue $17.44B (-9%); Op income $4.64B (-28%); NI $3.65B (-33%); EPS $6.83 (-29%). Japan: 16% sales growth FY25 driven by Miraito + Anshin Palette. Persistency 93.1%. US: $1.6B+ new annualized premium. Buyback $3.53B (+26%). FY26 guide: Japan UEP -1-2%, expense ratio 20-23%, benefit ratio 60-63%, pre-tax margin 33-36%. US NEP +3-6%, benefit ratio 48-52%, expense ratio 36-...
Key takeaways
- Japan sales +16% — outperforming sector. Driven by Miraito cancer insurance (+35.6% YoY) + Anshin Palette medical product. Third-sector protection emphasis (Tsumitasu repriced September). Persistency 93.1%.
- US new annualized premium $1.6B+ — solid. Continues digital + group + worksite expansion. Q4 expense ratio higher reflecting investment cycle.
- Reported earnings down 28-33% reflects FY24 mark-to-market base + reserve adjustments. Underlying core operations stable; FY25 GAAP volatility from investment portfolio + reserve actuarial assumptions normalizing.
- Massive buyback step-up. $-3.53B FY25 (vs $-2.80B FY24) — 26% acceleration. Capital return at scale supported by Japan capital strength + US business growth.
- FY26 guide segment-specific. Japan: UEP (underlying earned premium) -1-2%, expense ratio 20-23%, benefit ratio 60-63%, pre-tax margin 33-36%. US: NEP +3-6%, benefit ratio 48-52%, expense ratio 36-...%.
Business
Aflac is the dominant supplemental health + life insurance carrier in Japan + the United States. Two reporting segments:
- Japan (~55% of revenue, much higher of profit): Cancer + medical + life insurance. Distribution: independent corporate agencies + Daiichi Bank + JP Bank. Innovative "third-sector" products (Miraito cancer, Anshin Palette medical, Tsumitasu life).
- US (~45% of revenue): Voluntary worksite + group products through brokers. Cancer + accident + dental + vision + critical illness + life. Relationship-based distribution.
Strategic position: Aflac is the dominant insurer in Japanese supplemental health (cancer + medical) — a category that doesn't really exist in US to the same extent. US business is more fragmented but growing on digital + worksite + small-business expansion.
FY25 financial performance
| Metric (FY) | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue ($B) | 18.84 | 19.13 | 17.44 |
| Op income ($B) | 5.26 | 6.42 | 4.64 |
| Op margin | 27.9% | 33.5% | 26.6% |
| EBITDA ($B) | 5.26 | 6.42 | 5.53 |
| Net income ($B) | 4.66 | 5.44 | 3.65 |
| Diluted EPS ($) | 7.78 | 9.63 | 6.83 |
| FCF ($B) | 3.19 | 2.71 | 2.56 |
| Total debt ($B) | 7.36 | 7.50 | 8.41 |
| Dividends ($M) | -966 | -1,087 | -1,198 |
| Buyback ($B) | -2.80 | -2.80 | -3.53 |
The earnings print: Revenue -9% (currency + underlying premium dynamics + reserve actuarial). Op margin compressed to 26.6%. EPS -29%. The dispersion likely reflects FY24 base benefit + reserve normalization in FY25.
Capital allocation
- Capex: low (insurance company; capital consumed by reserve buildup).
- Dividends: $-1.20B FY25 (+10% YoY). Continues raise.
- Buybacks: $-3.53B FY25 (+26% YoY). Material acceleration.
- M&A: Bolt-on tuck-ins; expanded distribution channels in Japan (corporate, banks).
- Debt: $8.41B (+$0.91B YoY). Modest expansion.
FY26 outlook (per Q4 2025 call, 2026-02-05)
| FY26 Japan guide | Range |
|---|---|
| Underlying earned premiums | -1% to -2% |
| Expense ratio | 20% to 23% |
| Benefit ratio | 60% to 63% |
| Pre-tax profit margin | 33% to 36% |
| FY26 US guide | Range |
|---|---|
| Net earned premium growth | Lower end of 3% to 6% |
| Benefit ratio | 48% to 52% |
| Expense ratio | 36% to ... |
The Japan UEP -1-2% reflects portfolio mix shift + run-off of older policies. Pre-tax margin 33-36% is the segment profitability anchor. US growth +3-6% reflects new business + persistency improvement.
Key risks
- JPY/USD currency: Japan revenue translated to USD; major FX swing risk.
- Mortality / morbidity assumptions: Reserve adequacy on multi-decade liability tail.
- Investment portfolio: Aflac's portfolio of fixed-income + alternative investments; rates + credit cycle exposure.
- Japan demographics: Long-term aging + premium re-pricing risk on older policies.
- US distribution shift: Worksite + voluntary benefits cycle; digital disruption from competitors.
- Regulatory: US worksite product regulation + Japanese FSA capital rules.
Bottom line
AFL FY25 is the FY24-base normalization + Japan + US underlying strength year. Reported metrics down 28-33% on reserve + investment normalization, but Japan +16% sales + US $1.6B+ NAP + buyback $3.53B (+26%) all signal underlying strength. FY26 guide segment-specific with Japan UEP -1-2% / margin 33-36% + US NEP +3-6%. The structural read: dominant Japan supplemental health insurer + growing US worksite + consistent capital return. Risks are JPY/USD + reserve assumptions + Japan demographics.
Citations
- Aflac Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- Aflac Q4 2025 earnings call, 2026-02-05 — Japan 15.7% Q4 sales increase, 16% FY25; Miraito +35.6%; Anshin Palette positive reception; Tsumitasu repriced September; persistency 93.1%; US $1.6B+ NAP. FY26 guide: Japan UEP -1-2%, expense ratio 20-23%, benefit ratio 60-63%, pre-tax margin 33-36%; US NEP +3-6%, benefit ratio 48-52%.
- Internal financial_statements view (consolidated annual + cash flow + capital structure).